丹参注射液治疗妊娠期高血压疾病的临床观察

目的观察丹参注射液治疗妊娠期高血压疾病（HDCP）的临床疗效及安全性。方法将112例诊断为HDCP的患者随机分为治疗组和对照组各56例。两组的基础治疗相同,治疗组在此基础上加用复方丹参注射液治疗。结果在治疗后,两组孕妇的平均动脉压和尿蛋白含量均较治疗前有显著下降（P〈0.01）,而治疗组较对照组降低更明显（P〈0.01）。两组治疗后的凝血酶原时间（PT）、部分凝血活酶时间（APTT）均较治疗前显著延长（P〈0.01）,而纤维蛋白原（FIB）则较治疗前明显降低（P〈0.05）,但治疗组较对照组改善更明显（P〈0.01）。治疗组不良妊娠结局的发生率及剖宫产率均明显低于对照组（P〈0.05）。两组不良围产儿结局发生率比较,差异无统计学意义（P〉0.05）。结论丹参注射液治疗HDCP疗效肯定,不良反应少。

Clinical observation on Danshen injection in the treatment of patients with hypertensive disorder complicating pregnancy

[ Objective ] To observe the clinical effect of Danshen injection in the treatment of patients with hypertensive disorder complicating pregnancy（HDCP） and its safety. [ Methods ] 112 patients with HDCP were divided randomly into therapy group and control group with each group of 56 cases. Both groups received the same basic treatment, moreover, the therapy group was given with Danshen injection. [ Results ] The mean arterial pressure and urine protein content in both groups dropped significantly after treatment（both P〈0.01）, but they were more obvious in therapy group than the control（P〈0.01）. After treatment, the prothrombin time（PT）, activated partial thromboplastin time（APTF） lengthened and fibrinogen（FIB） dropped significantly in both groups （P〈0.01 or P〈0.05）, but they were more obvious in therapy group than the control（all P〈0.01）. Comparison with the control, the therapy group had lower incidence of had pregnant outcome and rate of abdominal delivery（P〈0.05）, but the incidence of bad perinatal infantile outcomes in both groups had no significant difference（P〉0.05）. [ Conclusion ] Danshen injection is effective for treating HDCP patients with few side reaction.